Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DAWN Day One Biopharmaceuticals	$6.41 -1.4%	$6.86	$6.08 ▼ $16.76	$658.86M	-1.3	1.13 million shs	1.32 million shs
ENGN enGene	$3.29 +1.2%	$3.74	$2.65 ▼ $11.00	$165.68M	-0.4	128,347 shs	20,801 shs
GHRS GH Research	$11.84 -1.3%	$10.92	$6.00 ▼ $20.50	$623.82M	0.97	189,481 shs	146,643 shs
KALV KalVista Pharmaceuticals	$12.31 +1.3%	$12.46	$7.30 ▼ $15.50	$603.80M	-0.01	463,005 shs	1.75 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DAWN Day One Biopharmaceuticals	-1.38%	-5.04%	-1.08%	-23.05%	-52.13%
ENGN enGene	+1.23%	+2.17%	-15.86%	-36.85%	-60.65%
GHRS GH Research	-1.25%	-14.14%	+1.20%	-1.91%	-1.00%
KALV KalVista Pharmaceuticals	+1.32%	-8.54%	+1.99%	+2.58%	+8.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DAWN Day One Biopharmaceuticals	1.751 of 5 stars	3.6	0.0	0.0	2.3	2.5	0.0
ENGN enGene	2.5563 of 5 stars	3.5	3.0	0.0	1.0	2.5	0.6
GHRS GH Research	1.8362 of 5 stars	3.5	0.0	0.0	2.8	2.5	0.0
KALV KalVista Pharmaceuticals	4.0035 of 5 stars	3.6	0.0	4.4	3.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DAWN Day One Biopharmaceuticals	3.13	Buy	$30.57	376.93% Upside
ENGN enGene	3.00	Buy	$23.29	607.77% Upside
GHRS GH Research	3.00	Buy	$32.00	170.27% Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	101.73% Upside

Current Analyst Ratings Breakdown

Latest ENGN, DAWN, GHRS, and KALV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
5/13/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $29.00
5/9/2025	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
5/7/2025	DAWN Day One Biopharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$25.00
5/7/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $27.00
4/29/2025	ENGN enGene	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$18.00 ➝ $18.00
4/8/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/3/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
3/26/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/26/2025	KALV KalVista Pharmaceuticals	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DAWN Day One Biopharmaceuticals	$131.16M	4.95	N/A	N/A	$4.99 per share	1.28
ENGN enGene	N/A	N/A	N/A	N/A	$4.46 per share	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	$3.44 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.71	N/A	N/A	N/A	-42.66%	-14.98%	-13.04%	7/8/2025 (Estimated)
ENGN enGene	-$55.14M	-$1.65	N/A	N/A	N/A	N/A	-32.60%	-28.26%	N/A
GHRS GH Research	-$38.96M	-$0.79	N/A	N/A	N/A	N/A	-19.20%	-18.40%	9/2/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-104.25%	-78.69%	7/10/2025 (Estimated)

Latest ENGN, DAWN, GHRS, and KALV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	N/A	N/A	N/A	N/A	N/A
6/10/2025	Q2 2025	ENGN enGene	-$0.4768	-$0.51	-$0.0332	-$0.51	N/A	N/A
5/8/2025	Q1 2025	GHRS GH Research	-$0.61	-$0.19	+$0.42	-$0.19	N/A	N/A
5/6/2025	Q1 2025	DAWN Day One Biopharmaceuticals	-$0.46	-$0.35	+$0.11	-$0.35	$30.28 million	$30.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
ENGN enGene	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DAWN Day One Biopharmaceuticals	N/A	10.62	10.55
ENGN enGene	0.09	12.66	12.66
GHRS GH Research	N/A	29.71	29.71
KALV KalVista Pharmaceuticals	N/A	10.44	10.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DAWN Day One Biopharmaceuticals	87.95%
ENGN enGene	64.16%
GHRS GH Research	56.90%
KALV KalVista Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
DAWN Day One Biopharmaceuticals	6.20%
ENGN enGene	10.40%
GHRS GH Research	41.60%
KALV KalVista Pharmaceuticals	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DAWN Day One Biopharmaceuticals	60	101.36 million	95.08 million	Optionable
ENGN enGene	31	50.98 million	45.68 million	N/A
GHRS GH Research	10	52.03 million	30.38 million	Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.50 million	Optionable

ENGN, DAWN, GHRS, and KALV Headlines

Recent News About These Companies

FDA delays decision on hereditary disease drug

June 18 at 6:23 PM | beckershospitalreview.com

KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down - What's Next?

June 16 at 1:21 PM | marketbeat.com

Makary Considers More Cuts at FDA Amid Continued Delays

June 16 at 10:41 AM | biospace.com

FDA Plans to Shrink; Nursing Shortage at Walter Reed; Pelvic Floor Therapy for Men?

June 16 at 10:41 AM | medpagetoday.com

DOGE cuts cause FDA to delay decision on hereditary disease drug

June 16 at 10:41 AM | msn.com

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

June 16 at 10:41 AM | biopharmadive.com

KalVista Pharmaceuticals Shares Edge Down on FDA Delays for Sebetralstat Application

June 16 at 10:41 AM | marketwatch.com

FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision

June 16 at 5:39 AM | fiercebiotech.com

FDA won’t meet PDUFA goal date for sebetralstat

June 14, 2025 | thepharmaletter.com

FDA Tells Drugmaker ‘Heavy Workload’ to Delay Approval Decision

June 13, 2025 | bloomberg.com

DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals’ Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints

June 13, 2025 | cantechletter.com

KalVista said FDA will not meet review date for sebetralstat

June 13, 2025 | msn.com

Health Sector Updates: Breakthroughs and Challenges

June 13, 2025 | devdiscourse.com

KalVista Pharmaceuticals Hit by FDA Delays

June 13, 2025 | marketwatch.com

US FDA extends review of KalVista's swelling disorder drug due to heavy workload

June 13, 2025 | reuters.com

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

June 13, 2025 | businesswire.com

Research Analysts Issue Forecasts for KALV FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Cantor Fitzgerald Comments on KALV FY2026 Earnings

June 11, 2025 | marketbeat.com

Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells 7,169 Shares of Stock

June 11, 2025 | insidertrades.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 7,169 Shares

June 10, 2025 | marketbeat.com

Bank of America Corp DE Has $932,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

June 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN, DAWN, GHRS, and KALV Company Descriptions

Day One Biopharmaceuticals NASDAQ:DAWN

$6.41 -0.09 (-1.38%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$6.41 0.00 (0.00%)

As of 06/18/2025 07:11 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

enGene NASDAQ:ENGN

$3.29 +0.04 (+1.23%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.30 +0.00 (+0.15%)

As of 06/18/2025 04:01 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

GH Research NASDAQ:GHRS

$11.84 -0.15 (-1.25%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$11.88 +0.04 (+0.30%)

As of 06/18/2025 07:23 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

KalVista Pharmaceuticals NASDAQ:KALV

$12.31 +0.16 (+1.32%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$12.32 +0.00 (+0.04%)

As of 06/18/2025 07:58 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time